<DOC>
<DOCNO>EP-0658550</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Amino acid salts of and methods for preparing antihypercholesterolemic tetrazole compounds.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3141	A61K3141	A61P300	A61P306	A61P4300	A61P4300	C07B5700	C07B5700	C07C22900	C07C22926	C07D25700	C07D25704	C07D40500	C07D40506	C12N999	C12N999	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	A61P	A61P	C07B	C07B	C07C	C07C	C07D	C07D	C07D	C07D	C12N	C12N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P3	A61P3	A61P43	A61P43	C07B57	C07B57	C07C229	C07C229	C07D257	C07D257	C07D405	C07D405	C12N9	C12N9	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of the formula 

wherein R¹ and R⁴ each are independently hydrogen, halogen, C₁₋₄ alkyl, 
C₁₋₄ alkoxy or trifluoromethyl;

 
   R², R³, R⁵ and R⁶ each are independently hydrogen, halogen, 

C₁₋₄ alkyl or C₁₋₄ alkoxy;
 

   R⁷ is an amino acid such as arginine or lysine; and
 

   tet is 

where R⁸ is 
hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxyalkyl or (2-methoxy-ethoxy)methyl; 

methods of preparing compouds of formula 

and intermediates. The compounds of formula I and II are inhibitors of 
the enzyme 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) 

reductase and are useful in the treatment of hypercholesterolemia, 
hyperlipoproteinemia and atherosclerosis. 
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The present invention is directed to the amino acid sets such as the 
L-arginine or lysine salts of the compounds of formula 
wherein R¹ and R⁴ are independently hydrogen, hydrogen, C₁₋₄ alkyl, C₁₋₄ 
alkoxy or trifluoromethyl;
 
   R², R³, R⁵ and R⁶ are independently hydrogen, halogen, C₁₋₄ 
alkyl or C₁₋₄ alkoxy;
 
   R⁷ is an amino acid; and
 
   tet is 
where R⁸ is 
hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxyalkyl or (2-methoxy-ethoxy)methyl. The invention also includes a novel process for preparing the 
lactones of formula  The invention also includes the crystalline hydrated species having 
the formula 
wherein X is preferably between about 0.45 to 0.65. Further, the invention includes a process for the continuous 
preparation of compounds of the formula 
including the steps of (a) heating a solution having a compound of formula  a brominating agent and a free radical initiator in a halogenated 
hydrocarbon solvent to a temperature of between about 30 to 35 °C; and 
(b) subsequently exposing the heated solution to UV or visible light. The compounds of formula I and II are potent inhibitors of the 
enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
and are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia 
and atherosclerosis. The compounds of formula III and IV are 
intermediates useful in the preparation of compounds of formula I and II. The present invention provides the amino acid salts of the formula 
I, compounds of formula III and methods of preparing the compounds of 
formula I, II and IV. Listed below are definitions of various terms used to 
describe the compounds of the instant invention. These definitions apply 
to the terms as they are used throughout the specification (unless they are 
otherwise limited in specific instances) either individually or as part of a 
larger group. The terms "C₁₋₄ alkyl", "C₁₋₆ alkyl" and "C₁₋₄ alkoxy" refer to 
unbranched or branched chain alkyl or alkoxy groups such as methyl, 
ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, amyl, hexyl, etc. 
Preferably, these groups contain from 1 to 4 carbon atoms and, most 
preferably, they contain 1 or 2 carbon atoms. The term "halogen" or "halide" as used herein refers to chlorine, 
fluorine, bromine and iodine. In the compounds of formula I and II, it is intended that all of the 
double bonds are in the trans configuration. i.e., (E), as indicated in the 
structural formulae used herein and in the claims.  As the compounds of the present invention may possess one or two 
asymmetric carbon
</DESCRIPTION>
<CLAIMS>
A compound of the formula 
 

wherein R¹ and R⁴ are independently hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ 
alkoxy or trifluoromethyl; 

   R², R³, R⁵ and R⁶ are independently hydrogen, halogen, C₁₋₄ 
alkyl or C₁₋₄ alkoxy; 

   R⁷ is an amino acid; and 
   tet is 

 
where R⁸ is 

hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxyalkyl or (2-methoxy-ethoxy)methyl. 
The compound of Claim 1 wherein R₁, R₂, R₃, R₄, R₅ and R₆ are 
independently hydrogen, halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy. 
The compound of Claim 1 wherein R₁ and R₄ are hydrogen and R₂, R₃, 
R₅ and R₆ are independently hydrogen, fluoro, chloro, methyl or methoxy. 
The compound of Claim 1 wherein tet is 1H-tetrazol-5-yl or 
1-substituted-1H-tetrazol-5-yl. 
The compound of Claim 2 wherein tet is 1H-tetrazol-5-yl or 
1-substituted-1H-tetrazol-5-yl. 
The compound of Claim 1 wherein tet is 1-methyl-1H-tetrazol-5-yl, 
1-ethyl-1H-tetrazol-5-yl, 1-methylethyl-1H-tetrazol-5-yl or 

1-(2-methoxyethoxy)-methyl-1H-tetrazol-5-yl. 
The compound of Claim 1 wherein tet is 1-methyl-1H-tetrazol-5-yl. 
The compound of Claim 5 wherein tet is 1-methyl-1H-tetrazol-5-yl. 
The compound of Claim 1 wherein the amino acid is L-arginine. 
The compound of Claim 8 wherein the amino acid is L-arginine. 
The compound of Claim 1 wherein the amino acid is lysine. 
The compound of Claim 8 wherein the amino acid is lysine. 
A method of preparing compounds of formula 
 

wherein R¹ and R⁴ are independently hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ 
alkoxy or trifluoromethyl; 

   R², R³, R⁵ and R⁶ are independently hydrogen, halogen, C₁₋₄ 
alkyl or C₁₋₄ alkoxy; and 

   tet is 
 

where R⁸ is 
hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxyalkyl or (2-methoxy-ethoxy)methyl; 

comprising the steps of (a) reacting a compound of formula  
with a compound of formula 

 
in the presence of a condensation agent to form compounds of formula 

 
(b) reacting compounds of formula IX with an acid to form a compound of 

formula 

 

(c) reacting the compound of formula X with a base followed by an acid to 
form the compounds of formula 

 
(d) reacting the compound of formula VI with cinchonidine to form a 

compound of formula 
 

(e) reacting the compound of formula XI with a coupling reagent or an 
activating agent to form the compounds of formula II. 
The method of Claim 13 wherein the condensation agent is KO-tAm 
or KO-t-Bu. 
The method of Claim 13 wherein the coupling reagent is pivaloyl 
chloride or DCC. 
A compound of the formula 
 

wherein R¹ and R⁴ are independently hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ 
alkoxy or trifluoromethyl; 

   R², R³, R⁵ and R⁶ are independently hydrogen, halogen, C₁₋₄ 
alkyl or C₁₋₄ alkoxy; and 

   X is from about 0.45 to about 0.65. 
A method of forming compounds of formula 
 

wherein R¹ and R⁴ are independently hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ 
alkoxy or trifluoromethyl; 

   R², R³, R⁵ and R⁶ are independently hydrogen, halogen, C₁₋₄ 
alkyl or C₁₋₄ alkoxy; and 

   tet is 
 

where R⁸ is 
hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxyalkyl or (2-methoxy-ethoxy)methyl; 

comprising the step of reacting a compound of formula  
with a compound of formula 

 
in the presence of a condensation agent in an organic solvent. 
A method of forming a compound of formula 
 

wherein R¹ and R⁴ are independently hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ 
alkoxy or trifluoromethyl; 

   R², R³, R⁵ and R⁶ are independently hydrogen, halogen, C₁₋₄ 
alkyl or C₁₋₄ alkoxy; and 

   tet is 
 

where R⁸ is 
hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxyalkyl or (2-methoxy-ethoxy)methyl; 

comprising the step of reacting compounds of formula  
with an acid, followed by a base and then an acid and reacting the product 

with cinchonidine. 
A method of forming compounds of formula 
 

wherein R¹ and R⁴ are independently hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ 
alkoxy or trifluoromethyl; 

   R², R³, R⁵ and R⁶ are independently hydrogen, halogen, C₁₋₄ 
alkyl or C₁₋₄ alkoxy; and 

   tet is 
 

where R⁸ is 
hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxyalkyl or (2-methoxy-ethoxy)methyl; 

comprising the steps of reacting a compound of formula 

 

with a coupling reagent or an activating agent. 
A method for the continuous preparation of compounds of the formula 
 

wherein R¹ and R⁴ are independently hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ 
alkoxy or trifluoromethyl; 

   R², R³, R⁵ and R⁶ are independently hydrogen, halogen, C₁₋₄ 
alkyl or C₁₋₄ alkoxy; and 

   tet is 
 

where R⁸ is 
hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxyalkyl or (2-methoxy-ethoxy)methyl 

comprising the step of exposing a continuous stream of a heated solution 
comprising a compound of formula 

 
a brominating agent, a free radical initiator and a halogenated hydrocarbon 

solvent to UV or visible light. 
The method of Claim 20 wherein the brominating agent is 1,3-dibromo-5,5-dimethylhydantoin. 
The method of Claim 20 wherein the free radical initiator is di(4-tert-butylcyclohexyl)peroxydicarbonate. 
The method of Claim 20 wherein the halogenated hydrocarbon 
solvent is methylene chloride. 
The method of Claim 20 wherein the heated solution is at a 
temperature between about 30°C to 35°C. 
</CLAIMS>
</TEXT>
</DOC>
